- Home
- SOAR vs CYCC Comparison
SOAR vs CYCC Comparison
Compare SOAR & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- CYCC
- Stock Information
- Founded
- SOAR 2021
- CYCC 1992
- Country
- SOAR United States
- CYCC United States
- Employees
- SOAR N/A
- CYCC N/A
- Industry
- SOAR Blank Checks
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- CYCC Health Care
- Exchange
- SOAR Nasdaq
- CYCC Nasdaq
- Market Cap
- SOAR 3.8M
- CYCC 3.6M
- IPO Year
- SOAR N/A
- CYCC N/A
- Fundamental
- Price
- SOAR $1.63
- CYCC $0.25
- Analyst Decision
- SOAR
- CYCC Strong Buy
- Analyst Count
- SOAR 0
- CYCC 1
- Target Price
- SOAR N/A
- CYCC $11.00
- AVG Volume (30 Days)
- SOAR 404.0K
- CYCC 160.2K
- Earning Date
- SOAR 05-14-2025
- CYCC 05-13-2025
- Dividend Yield
- SOAR N/A
- CYCC N/A
- EPS Growth
- SOAR N/A
- CYCC N/A
- EPS
- SOAR N/A
- CYCC N/A
- Revenue
- SOAR $46,288,000.00
- CYCC $74,000.00
- Revenue This Year
- SOAR N/A
- CYCC N/A
- Revenue Next Year
- SOAR N/A
- CYCC $88.68
- P/E Ratio
- SOAR N/A
- CYCC N/A
- Revenue Growth
- SOAR 97.25
- CYCC N/A
- 52 Week Low
- SOAR $1.31
- CYCC $0.22
- 52 Week High
- SOAR $90.00
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- SOAR 34.61
- CYCC 29.30
- Support Level
- SOAR $1.31
- CYCC $0.29
- Resistance Level
- SOAR $2.24
- CYCC $0.32
- Average True Range (ATR)
- SOAR 0.25
- CYCC 0.02
- MACD
- SOAR 0.08
- CYCC -0.00
- Stochastic Oscillator
- SOAR 31.07
- CYCC 19.92
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.